Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paediatric monthly recombinant factor XIII replacement therapy in congenital factor XIII A-subunit deficiency
2010-020192-23Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of catridecacog in Factor XIII A subunit deficiency, sponsored by Novo Nordisk. Started Aug 2010; status: completed.
02
Drugs
catridecacog
03
Conditions
Factor XIII A subunit deficiency
Beyond the preview
Go deeper on 2010-020192-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020192-23.